Physician profile
Aaron Cohen
NPI 1356373534
$1,562.57
in general payments reported to CMS, 2019-2025
17 companies · $392 in 2025
The $392 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $64.98 · 2021: $209 · 2022: $125 · 2023: $240 · 2024: $343 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $975.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $975.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $364.47 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Oyster Point Pharma, INC. | $205.13 | 2023-2024 | Tyrvaya, Ryzumvi |
| Aerie Pharmaceuticals, INC. | $187.41 | 2019-2021 | |
| Alcon Vision LLC | $184.57 | 2019-2025 | Rocklatan |
| Sun Pharmaceutical Industries INC. | $122.13 | 2019-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $91.33 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $72.57 | 2025 | Miebo, Vyzulta |
| Allergan, INC. | $69.23 | 2019-2022 | |
| Astellas Pharma US INC | $63.08 | 2024 | Izervay |
| Horizon Therapeutics Plc | $34.16 | 2021-2023 | Tepezza |
| Thea Pharma INC. | $30.28 | 2024 | Iyuzeh |
| Amgen INC. | $28.05 | 2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $25.00 | 2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $24.39 | 2019 | |
| Coopervision INC. | $22.38 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $21.54 | 2024 | Rayner Cataract Set 1, Rayone Spheric, Rayone Aspheric |
| Harrow Eye, LLC | $16.85 | 2025 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.